Company Overview
Company Type: Public Company
Website: www.gsk.com
Number of Employees: 69,400
Ticker: GSK (LSE)
Year Founded: 1715


Business Description
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.

Financial Information (Currency: CAD, in mm) 
Total Revenue
49,084.2
Market Capitalization
103,161.5
TEV/Total Revenue
2.6x
EBITDA
16,522.0
Total Enterprise Value
127,320.4
TEV/EBITDA
7.7x
EBIT
13,336.1
Cash & ST Invst.
10,883.0
P/Diluted EPS Before Extra
11.6x
Net Income
25,818.8
Total Debt
35,932.1
Price/Tang BV
NM
Capital Expenditure
(2,078.2)
Total Assets
99,495.2
Total Debt/EBITDA
2.2x
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-10-2023


Estimates & Guidance Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Guidance Current FQ
Current FY
Guidance Current FY
NTM
EPS Normalized
0.75
-
2.51
2.66 - 2.73
2.55
Revenue (mm)
12,750.38
-
48,805.19
52,992.80 - 53,974.15
50,146.90
EBITDA (mm)
4,966.41
-
17,076.32
-
17,397.36

Forward Multiples (Current FY)

Price/Earnings
10.14x
TEV/REV
2.61x
TEV/EBITDA
7.45x
PEG
1.49x
P/BV
4.76x

Non-Periodic Estimates

Recommendation
Outperform (2.45)
Target Price
28.87
Potential Upside
13.57%
LT Growth (%)
6.81%


Key Professionals
Name
Title
Walmsley, Emma Natasha
CEO & Director
Brown, Julie Belita
CFO & Executive Director
Ramakrishnan, Shobie 
Chief Digital & Technology Officer
Wood, Tony 
Chief Scientific Officer
Elton-Farr, Sarah 
Head of Investor Relations
Ford, James 
Senior VP & Group General Counsel of Legal & Compliance
Jackson, Sally 
Senior Vice President of Global Communications & CEO Office
Redfern, David Simon
President of Corporate Development
Conrad, Diana 
Chief People Officer
Altshul, Amy 
Senior Vice President of Legal, R&D and Global Commercial Franchises
Branson, Kim 
Senior VP and Global Head of Artificial Intelligence & Machine Learning
Breuer, Thomas 
Chief Medical Officer of GSK Vaccines

Key Board Members
Name
Title
Symonds, Jonathan Richard
Non-Executive Chairman
Walmsley, Emma Natasha
CEO & Director
Brown, Julie Belita
CFO & Executive Director
Bancroft, Charles A.
Senior Independent Non-Executive Director
Rohner, Urs 
Independent Non-Executive Director
Anderson, Elizabeth McKee
Independent Non-Executive Director
Barron, Hal V.
Non-Executive Director
Beal, Anne C.
Independent Non-Executive Director
Becker, Wendy 
Non-Executive Director
Dietz, Harry C.
Independent Non-Executive Director
Goodman, Jesse L.
Independent Non-Executive Director
Sikka, Vishal 
Independent Non-Executive Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
980 Great West Road Middlesex | Brentford, Greater London | TW8 9GS | United Kingdom
Phone: 44 20 8047 5000   

Current and Pending Investors
Bluebell Capital Partners Limited, Elliott Management Corporation, Elo Mutual Pension Insurance Company, Ilmarinen Mutual Pension Insurance Company, Sculptor Capital Management, Inc. (NYSE:SCU), TRC Capital Investment Corporation, Wellcome Trust, Investment Division

Prior Investors
Healthcare Royalty Management, LLC, Woodford Asset Management LLP, Woodford Investment Management Ltd.

Investment Arms
Action Potential Venture Capital Limited, Glaxo Wellcome Pension Plan, GlaxoSmithKline Employee Trust, GlaxoSmithKline Master Retirement Trust, GlaxoSmithKline plc, Asset Management Arm, GlaxoSmithKline plc, Investment Arm, GSK Pension Scheme, GSK Ventures (Prior), SR One Capital Management, LP

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 25.42
Market Cap (mm)
103,012.4
Open
 25.97
Shares Out. (mm)
4,052.3
Previous Close
 25.42
Float %
96.8%
Change on Day
(0.04)
Shares Sold Short (mm)
-
Change % on Day
(0.1)%
Dividend Yield %
4.0%
Day High/Low
 26.16/ 25.33
Diluted EPS Excl. Extra Items
2.19
52 wk High/Low
 26.92/ 21.80
P/Diluted EPS Before Extra
11.64x
Volume (mm)
6.21
Avg 3M Dly Vlm (mm)
6.95
Beta 5Y
0.29


 
Delayed Quote** | Last Updated on Oct-11-2023 12:00 AM (GMT-5)
LSE:GSK - Common Stock


Index Membership
S&P Global 100 Index;S&P Global 1200;S&P Global 1200 Health Care Index;S&P Developed BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Asia-Pacific BMI Growth Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific LargeMidCap Health Care (Sector) Index;S&P Developed BMI Index;S&P Developed Ex-Asia-Pacific BMI Growth Index;S&P Developed Ex-Asia-Pacific LargeMidCap Growth Index;S&P Developed Ex-Australia BMI Index;S&P Developed Ex-Australia LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Growth Index;S&P Developed BMI Growth Index;S&P Developed Ex-Asia-Pacific BMI Index;S&P DM Ex-Asia-Pacific BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia LargeMidCap Index;S&P Developed Ex-Canada BMI Index;S&P Developed Ex-Canada BMI Health Care (Sector) Index;S&P Developed Ex-Canada BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Canada LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-Switzerland BMI Index;S&P Developed Ex-Switzerland LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Index;S&P Developed Ex-Eurozone LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Eurozone LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Japan BMI Index;S&P Developed Ex-Japan BMI Growth Health Care (Sector) Index;S&P Developed Ex-Japan BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific LargeMidCap Index;S&P Developed Ex-Asia-Pacific LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Australia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-Japan LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-Switzerland BMI Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Eurozone LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-Australia BMI Growth Index;S&P Developed Ex-Australia BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia BMI Health Care (Sector) Index;S&P Developed Ex-Canada BMI Growth Health Care (Sector) Index;S&P DM Ex-Canada LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. & Japan BMI Growth Index;S&P DM Ex-U.S. & Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland LargeMidCap Index;S&P Developed Ex-Switzerland LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan LargeMidCap Index;S&P Developed Ex-U.S. & Japan LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-U.S. BMI Growth Health Care (Sector) Index;S&P Developed Ex-U.S. LargeMidCap Growth Index;S&P EPAC LargeMidCap Growth Health Care (Sector) Index;S&P Europe BMI Growth Index;S&P Europe BMI Growth Health Care (Sector) Index;S&P Europe Ex-Switzerland BMI Growth Index;S&P Europe Ex-Switzerland BMI Health Care (Sector) Index;S&P Europe Ex-Switzerland LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P EPAC BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P EPAC Ex-Japan BMI Index;S&P Developed Ex-Eurozone Over USD5 Billion Index;S&P Developed Ex-Switzerland LargeMidCap Growth Index;S&P Europe Ex-Switzerland LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-Canada BMI Growth Index;S&P Developed Ex-U.S. & Japan BMI Index;S&P Developed Ex-U.S. & Japan BMI Growth Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan BMI Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan LargeMidCap Growth Index;S&P Europe LargeMidCap Index;S&P Europe LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Over USD5 Billion Index;S&P Developed Ex-Eurozone BMI Growth Health Care (Sector) Index;S&P Developed Ex-Japan LargeMidCap Index;S&P Europe, Mid-East & Africa BMI Index;S&P Europe, Mid-East & Africa BMI Health Care (Sector) Index;S&P Developed Ex-U.S. BMI Growth Index;S&P Developed Ex-U.S. LargeMidCap Health Care (Sector) Index;S&P Developed Ex-U.S. BMI Index;S&P Developed Ex-U.S. BMI Health Care (Sector) Index;S&P DM Ex-U.S. LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia Over USD5 Billion Index;S&P Developed Ex-Canada LargeMidCap Index;S&P Developed Ex-Canada Over USD5 Billion Index;S&P Developed Over USD5 Billion Index;S&P Global BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia BMI Health Care (Sector) Index;S&P EPAC BMI Growth Health Care (Sector) Index;S&P EPAC Ex-Japan BMI Growth Index;S&P EPAC Ex-Japan Over USD5 Billion Index;S&P Developed Ex-Eurozone LargeMidCap Index;S&P Developed Ex-Japan LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Switzerland BMI Growth Index;S&P Developed Ex-Switzerland BMI Growth Health Care (Sector) Index;S&P DM Ex-Switzerland BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Global Ex-U.S. BMI Health Care (Sector) Index;S&P Developed LargeMidCap Index;S&P Developed LargeMidCap Growth Index;S&P Developed LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland Over USD5 Billion Index;S&P EPAC Ex-Japan LargeMidCap Growth Health Care (Sector) Index;S&P EPAC Ex-Japan LargeMidCap Health Care (Sector) Index;S&P Europe BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P EPAC LargeMidCap Index;S&P EPAC Over USD5 Billion Index;S&P Europe, Mid-East & Africa BMI Growth Index;S&P Developed BMI Growth Health Care (Sector) Index;S&P Europe Over USD5 Billion Index;S&P Europe, Mid-East & Africa Over USD5 Billion Index;S&P Europe, Mid-East & Africa LargeMidCap Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Health Care (Sector) Index;S&P Developed Ex-Eurozone LargeMidCap Growth Index;S&P Developed Ex-Japan LargeMidCap Growth Index;S&P DM Ex-Japan LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan Over USD5 Billion Index;S&P Global Ex-Japan Over USD5 Billion Index;S&P Global Ex-Pan Asia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia LargeMidCap Growth Index;S&P Global Ex-U.S. BMI Growth Index;S&P Global BMI Index;S&P Global Ex-U.S. LargeMidCap Growth Index;S&P Global Ex-Japan BMI Health Care (Sector) Index;S&P Global Ex-Japan LargeMidCap Index;S&P Global Ex-Pan Asia Over USD5 Billion Index;S&P Global Ex-U.S. LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. LargeMidCap Growth Health Care (Sector) Index;S&P EPAC BMI Index;S&P EPAC BMI Growth Index;S&P EPAC Ex-Japan BMI Health Care (Sector) Index;S&P Europe BMI Index;S&P EPAC BMI Health Care (Sector) Index;S&P Europe, ME & Africa BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Europe, Mid-East & Africa LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P EPAC Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P EPAC LargeMidCap Growth Index;S&P EPAC LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Europe Ex-Switzerland BMI Growth Health Care (Sector) Index;S&P Europe Ex-Switzerland LargeMidCap Growth Index;S&P Europe LargeMidCap Growth Index;S&P Europe, Mid-East & Africa LargeMidCap Growth Index;S&P Global Ex-Pan Asia LargeMidCap Health Care (Sector) Index;S&P Global Ex-U.S. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Over USD5 Billion Index;S&P Pan Europe LargeMidCap Index;S&P Pan Europe LargeMidCap Health Care (Sector) Index;S&P Pan Europe LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Japan LargeMidCap Health Care (Sector) Index;S&P Global Ex-Japan LargeMidCap Pharmaceuticals, Biotech & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. BMI Index;S&P United Kingdom BMI Growth Index;S&P Global LargeMidCap Health Care (Sector) Index;S&P United Kingdom BMI Growth Health Care (Sector) Index;S&P United Kingdom LargeMidCap Growth Index;S&P United Kingdom LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. & Japan Over USD5 Billion Index;S&P United Kingdom Over USD5 Billion Index;S&P Developed Ex-U.S. LargeMidCap Index;S&P Pan Europe BMI Health Care (Sector) Index;S&P EPAC Ex-Japan BMI Growth Health Care (Sector) Index;S&P EPAC Ex-Japan LargeMidCap Index;S&P Europe Ex-Switzerland BMI Index;S&P Europe Ex-Switzerland LargeMidCap Index;S&P Europe Ex-Switzerland Over USD5 Billion Index;S&P Europe LargeMidCap Growth Health Care (Sector) Index;S&P Europe LargeMidCap Health Care (Sector) Index;S&P Pan Europe BMI Growth Index;S&P Global BMI Growth Index;S&P United Kingdom BMI Index;S&P United Kingdom LargeMidCap Index;S&P Global Ex-Japan BMI Growth Index;S&P Global Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Japan LargeMidCap Growth Index;S&P Global Ex-Pan Asia BMI Index;S&P Global Ex-Pan Asia BMI Growth Index;S&P Global Ex-Pan Asia LargeMidCap Index;S&P Global Ex-Pan Asia LargeMidCap Pharmaceuticals, Biotech & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. LargeMidCap Index;S&P Global Ex-U.S. Over USD5 Billion Index;S&P Global LargeMidCap Index;S&P United Kingdom LargeMidCap Growth Health Care (Sector) Index;S&P United Kingdom LargeMidCap Health Care (Sector) Index;S&P Global LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Pan Europe Over USD5 Billion Index;S&P United Kingdom BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific BMI Health Care (Sector) Index;S&P Developed Ex-Australia LargeMidCap Growth Index;S&P Developed Ex-Australia LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Canada LargeMidCap Growth Index;S&P Developed Ex-Canada LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Japan BMI Growth Index;S&P Developed Ex-U.S. & Japan LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. Over USD5 Billion Index;S&P Developed LargeMidCap Growth Health Care (Sector) Index;S&P Developed LargeMidCap Health Care (Sector) Index;S&P EPAC Ex-Japan LargeMidCap Growth Index;S&P EPAC Ex-Japan LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P EPAC LargeMidCap Health Care (Sector) Index;S&P Europe BMI Health Care (Sector) Index;S&P Europe Ex-Switzerland BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Europe Ex-Switzerland LargeMidCap Health Care (Sector) Index;S&P Europe, Mid-East & Africa LargeMidCap Index;S&P Global BMI Health Care (Sector) Index;S&P Global Ex-Japan BMI Index;S&P Global Ex-U.S. LargeMidCap Health Care (Sector) Index;S&P Global LargeMidCap Growth Index;S&P Pan Europe BMI Index;S&P Pan Europe BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Pan Europe LargeMidCap Growth Index;S&P United Kingdom BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P EPAC BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Japan BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Europe BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P EPAC Ex-Japan BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Eurozone BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Europe Ex-Switzerland BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. & Japan BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Canada BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Asia Pacific BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P United Kingdom BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Australia BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P EPAC Ex-Israel BMI Growth Index;S&P EPAC Ex-Israel BMI Growth Health Care (Sector) Index;S&P Developed Ex-Israel BMI Growth Index;S&P Developed Ex-Israel BMI Growth Health Care (Sector) Index;S&P EPAC Ex-Israel BMI Index;S&P EPAC Ex-Israel BMI Health Care (Sector) Index;S&P EPAC Ex-Israel BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel BMI Index;S&P Developed Ex-Israel BMI Health Care (Sector) Index;S&P Developed Ex-Israel BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P EPAC Ex-Israel LargeMidCap Growth Index;S&P EPAC Ex-Israel LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-Israel LargeMidCap Growth Index;S&P Developed Ex-Israel LargeMidCap Growth Health Care (Sector) Index;S&P EPAC Ex-Israel LargeMidCap Index;S&P EPAC Ex-Israel LargeMidCap Health Care (Sector) Index;S&P EPAC Ex-Israel LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel LargeMidCap Index;S&P Developed Ex-Israel LargeMidCap Health Care (Sector) Index;S&P DM Ex-Israel LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P EPAC Ex-Israel Over USD5 Billion Index;S&P Developed Ex-Israel Over USD5 Billion Index;S&P EUROPE 350;S&P EUROPE 350 - Health Care (Sector);S&P EUROPE 350 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Global 1200 - Pharmaceuticals (Industry);S&P Global 1200 - Pharmaceuticals (Sub Ind);S&P Global 1200 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P International 700;S&P International 700 Health Care (Sector);S&P Global Ex-Australia BMI Index;S&P Developed Ex-Continental Europe BMI Index;S&P Developed Ex-Japan, Ex-South Korea BMI Index;S&P Developed BMI Ex-U.S. & Korea LargeMidcap Index;S&P Developed BMI Ex-U.S. & Korea Index;Euronext Vigeo Europe 120 Index;Euronext Vigeo United Kingdom 20 Index;S&P EPAC Ex-Korea BMI;S&P EPAC Ex-Korea LargeMidCap;S&P DM Ex.Japan LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Global Ex-Australia LargeMidCap;S&P Developed Ex-Japan & South Korea LargeMidCap;EN Europe Sustainable 100 EW;S&P DM Ex-Israel LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group;S&P Developed Ex-Switzerland LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subs;S&P Developed Ex-Australia LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsec;S&P DM Ex-Canada LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group;S&P Developed Ex-Israel BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P EPAC Ex-Israel BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P Developed LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Europe Ex-Switzerland LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P Europe LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Sub;S&P EPAC LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia-Pacific LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Sub;S&P DM Ex-U.S. LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P EPAC Ex-Israel LargeMidCap Growth Pharmaceuticals, Biotech & Life Sciences (Industry Group);S&P EPAC Ex-Japan LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P United Kingdom LargeMidCap Growth Pharmaceuticals, Biotech & Life Sciences (Industry Group);S&P United Kingdom LargeCap;S&P UNITED KINGDOM Index;S&P Global Ex-Australia & New Zealand LargeMidCap;S&P Global Ex-China A BMI;S&P Global Ex-China A LargeMidCap;S&P Global Ex-U.S. & China A BMI;S&P Global Ex-U.S. & China A LargeMidCap;S&P Developed Ex-Korea BMI;S&P Global Ex-Japan & China A LargeMidCap;S&P Developed Ex-Korea LargeMidCap;S&P United Kingdom BMI Health Care;S&P Developed BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Canada BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P EPAC Ex-Japan BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan LargeMidCap Grwth Pharma, Biotech & Life Sciences (Industry Group);S&P Europe Ex-Switzerland BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia BMI Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland LargeMidCap Grwth Pharma, Biotech & Life Sciences (Industry Group);S&P Europe BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Canada LargeMidCap Growth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Europe Ex-Switzerland LargeMidCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. LargeMidCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P EPAC BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P United Kingdom LargeMidCap Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan LargeMidCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P United Kingdom BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P EPAC Ex-Israel LargeMidCap Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific LargeMidCap Grwth Pharma, Biotech & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia LargeMidCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone LargeMidCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel LargeMidCap Growth Pharma, Biotechnology & Life Sciences (Industry Group);S&P UNITED KINGDOM - Health Care (Sector) Index;S&P Global 100 Capped Index;S&P Developed Ex-Korea BMI Growth;S&P Developed Ex-Korea LargeMidCap Growth;S&P EPAC Ex-Korea BMI Growth;S&P EPAC Ex-Korea LargeMidCap Growth;S&P Global 1200 Ex-Canada;S&P Developed Ex-Korea LargeMidCap Health Care (Sector) Index;"S&P Developed Ex-Korea LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);EN Europe SBT 1 5


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
BELLUS Health Inc.
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

United States and Canada
Biotechnology
0.00
380.00
1.00
Affinivax, Inc.
Affinivax, Inc., a clinical-stage biopharmaceutical company that focuses on developing multiple antigen-presenting system (MAPS) technology-based vaccines that protect against various infectious diseases afflicting children and adults around the globe. Its MAPS technology enables the binding of protective polysaccharides and proteins in a single vaccine and induces a protective immune response. The company's vaccine pipeline programs to target various pathogens, such as streptococcus pneumoniae (pneumococcus), bacterial nosocomial infections, salmonella typhi, and staphylococcus aureus. Affinivax, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of August 16, 2022, Affinivax, Inc. operates as a subsidiary of GSK plc.

United States and Canada
Biotechnology
26.00
-
-
Sierra Oncology, Inc.
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California with an additional location in Vancouver, Canada. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.

United States and Canada
Biotechnology
0.00
280.00
6.00
Tesaro, Inc.
Tesaro, Inc., an oncology-focused biopharmaceutical company that identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022, which is in a phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in a phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreements with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd., as well as Genentech. Tesaro, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts. As of January 22, 2019, Tesaro, Inc. operates as a subsidiary of GSK plc.

United States and Canada
Biotechnology
219.00
711.00
644.00
Glaxo Saudi Arabia Limited
Glaxo Saudi Arabia Limited manufactures and markets pharmaceutical products, over the counter OTC medicines, and health related consumer products. The company offers prescription medicines to treat a range of conditions, such as infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also markets approximately 25 vaccines to prevent life-threatening or crippling illnesses, such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis. In addition, the company offers OTC medicines, such as alli, a weight loss medicine; Gaviscon, an antacid product; Panadol, a paracetamol-based pain reliever; smoking control products under NiQuitin and Nicorette names; and other brands, including Breathe Right nasal strips and snore relief products. Its oral healthcare products primarily comprise Aquafresh, a range of toothpastes, toothbrushes, and mouthwashes; and Sensodyne, a range of toothbrushes, toothpastes, mouthwashes, and dental floss. Further, the company provides nutritional healthcare products, such as Lucozade, a range of energy and sports drinks; Horlicks, a nutritional drink made from wheat, milk, and malted barley; and Ribena, a blackcurrant juice-based drink. Additionally, it offers products for dermatological treatments, pain relief, allergy treatment, cold and flu treatment, gastrointestinal conditions, feminine hygiene, nicotine replacement therapy, and HIV treatment. Glaxo Saudi Arabia Limited is based in Jeddah, Saudi Arabia. Glaxo Saudi Arabia Limited operates as a subsidisary of GlaxoSmithKline plc Glaxo Saudi Arabia Limited operates as a subsidiary of GSK plc

Africa / Middle East
Pharmaceuticals
53.00
-
-
GlycoVaxyn AG
GlycoVaxyn AG, a biotechnology company, develops bio conjugate vaccines to prevent and treat bacterial infections. It develops and produces immunogenic glycoprotein conjugate vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GSK plc

Europe
Biotechnology
-
-
-
Novartis AG, Global Vaccines Business
As of March 2, 2015, Global Vaccines Business of Novartis AG was acquired by GlaxoSmithKline plc. Global Vaccines Business of Novartis AG develops and supplies vaccines.

Europe
Pharmaceuticals
-
-
-

Investments as an LP
AMR Action Fund GP, Llc, AMR Action Fund, L.P., Dementia Discovery LP, EQT Life Sciences, EuclidSR Partners, Global Health Investment Fund I, LLC, Hatteras Venture Advisors VI, LLC, Hatteras Venture Partners V, LP, Index Life VI, Index Ventures SA, Inserm Transfert Initiative, Intel 64 Fund, Intel Capital Corporation, Kurma Biofund II, Kurma Partners SA, LHGP Asset Management LLP, Life Sciences Partners IV, L.P., Longwood Founders Fund, L.P., Longwood Fund, Medicxi Ventures (UK) LLP, Medicxi Ventures 1, Sanderling Ventures, Sanderling Ventures VII, SV Health Investors, LLC


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Oct-06-2023
Oct-06-2023
Merger/Acquisition
Seller
Haleon plc (LSE:HLN)

GSK plc (LSE:GSK)
1,084.30
Apr-18-2023
Jun-28-2023
Merger/Acquisition
Buyer
BELLUS Health Inc.
GSK plc (LSE:GSK)

1,970.57
Dec-13-2022
-
Private Placement
Buyer
Wave Life Sciences Ltd. (NasdaqGM:WVE)
GSK plc (LSE:GSK)

50.00
Sep-21-2022
Nov-08-2022
Private Placement
Buyer
Spero Therapeutics, Inc. (NasdaqGS:SPRO)
GSK plc (LSE:GSK)

9.00
Jul-27-2022
Mar-20-2023
Shelf Registration
Seller
Haleon plc (LSE:HLN)

GSK plc (LSE:GSK),Pfizer Inc. (NYSE:PFE),Glaxo Group Limited
16,067.76
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-11-2023
Lawsuits & Legal Issues
GSK plc Announces Update on Zantac (Ranitidine) Litigation
Oct-10-2023
Company Conference Presentations
GSK plc Presents at Festival of Biologics 2023, Oct-10-2023
Oct-09-2023
Client Announcements
GSK plc and Zhifei Announce Exclusive Strategic Vaccine Partnership in China
Oct-09-2023
Company Conference Presentations
GSK plc Presents at SAP Spend Connect Live, Oct-09-2023
Oct-08-2023
Company Conference Presentations
GSK plc Presents at HLTH 2023, Oct-08-2023

Competitors
3M Company (NYSE:MMM), A. Menarini Industrie Farmaceutiche Riunite S.r.l., Abbott Nutrition Manufacturing Inc., Acasti Pharma Inc. (NasdaqCM:ACST), Acino Pharma Gmbh, Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Actelion Ltd, Adimmune Corporation (TWSE:4142), Advil Spa, AIM ImmunoTech Inc. (NYSEAM:AIM), Akari Therapeutics, Plc (NasdaqCM:AKTX), Akebia Therapeutics, Inc. (NasdaqCM:AKBA), Akorn Operating Company LLC, Akzo Nobel N.V. (ENXTAM:AKZA), Al - Namura, Spol. S R.O., Alcon Inc. (SWX:ALC), Alexion Pharmaceuticals, Inc., Alkeus Pharmaceuticals, Inc., Allergan Finance, LLC, Allurion Technologies Inc. (NYSE:ALUR), Altiris Therapeutics, Inc., Ambev S.A. (BOVESPA:ABEV3), Amerge Corp., Amgen Inc. (NasdaqGS:AMGN), Amoun Pharmaceutical Company S.A.E., Antares Pharma, Inc., Apellis Pharmaceuticals, Inc. (NasdaqGS:APLS), Apricus Biosciences, Inc. (Acquired), Archer-Daniels-Midland Company (NYSE:ADM), Arena Pharmaceuticals, Inc. (Acquired), Arkema Inc., Astellas Pharma Inc. (TSE:4503), AstraZeneca PLC (LSE:AZN), Athena Diagnostics, Inc., Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH), B. Braun Melsungen AG, Bath & Body Works, Inc. (NYSE:BBWI), Bausch Health Companies Inc. (NYSE:BHC), Bayer Ag, Bayer Aktiengesellschaft (XTRA:BAYN), Bayer Vietnam Ltd., Becton, Dickinson and Company (NYSE:BDX), Bedford Laboratories, Beiersdorf Aktiengesellschaft (XTRA:BEI), Ben Tre Pharmaceutical Joint Stock Company (HOSE:DBT), Beroni Group Limited (NSX:BTG), Bharat Biotech Ltd., Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (HOSE:DBD), BioLineRx Ltd. (TASE:BLRX), BioNTech SE (NasdaqGS:BNTX), Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., Bolts Energy, LLC, Bomba USA, LLC, BombaU Energy Drink Korlatolt Felelossegu Tarsasag, bonyf N.V. (ENXTPA:MLBON), Brioschi Pharmaceuticals International, LLC, Bristol-Myers Squibb Company (NYSE:BMY), Bristol-Myers Squibb de Mexico S. de R. L. de C.V., Bullitt Beverage Company, Burt's Bees, Inc., Carabao Tawandang Company Limited, Cardax, Inc. (OTCPK:CDXI), Carlsberg Kazakhstan, CCA Industries, Inc. (OTCPK:CAWW), Celgene Corporation, Cell Cure Neurosciences Ltd., Cellular Biomedicine Group, Inc., Chandra Bhagat Pharma Limited (BSE:542934), Chanel S.A., ChemoCentryx, Inc., Chemokine Therapeutics Corporation (Out of Business), Chiesi Farmaceutici S.p.A., Chiesi Ltd., Chill Beverages International (Pty) Ltd, Chiron, Corp. (Acquired), Chugai Pharmaceutical Co., Ltd. (TSE:4519), Clariant AG (SWX:CLN), Codexis, Inc. (NasdaqGS:CDXS), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Coland Holdings Limited, Colgate-Palmolive Company (NYSE:CL), Combe Incorporated, Corteva, Inc. (NYSE:CTVA), CoTherix, Inc., Coty Inc. (NYSE:COTY), Croda International Plc (LSE:CRDA), CSL Limited (ASX:CSL), CureVac N.V. (NasdaqGM:CVAC), Cuu Long Pharmaceutical Joint Stock Company (HOSE:DCL), Dali Foods Group Co., Ltd., Danone S.A. (ENXTPA:BN), Dark Dog Trading GmbH, DCL Medical Laboratories, LLC, DenTek Oral Care, Inc., DHG Pharmaceutical Joint Stock Company (HOSE:DHG), Dimerix Limited (ASX:DXB), Diocle S.p.A., Domesco Medical Import - Export Joint-Stock Corporation (HOSE:DMC), Dong-A Pharmaceutical Co., Ltd., Dr. Reddy's Laboratories Limited (BSE:500124), Dr. Reddy’s Laboratories Ltd., Drinkoftheweek, LLC, Dynavax Technologies Corporation (NasdaqGS:DVAX), Eastroc Beverage (Group) Co.,Ltd. (SHSE:605499), Elder Pharmaceuticals Limited, Eli Lilly and Company (NYSE:LLY), Eli Lilly and Company Limited, EMD Millipore Corporation, Enzymotec Ltd., eos Products, LLC, Eva Pharma, F. Hoffmann-La Roche Ltd, Fabino Life Sciences Limited (BSE:543444), FibroGen, Inc. (NasdaqGS:FGEN), Flash Beverage Company, Fletcher/CSI, LLC, FoodCare Sp. z o.o., Fresenius Kabi Aktiengesellschaft, Fresenius Medical Care Holdings, Inc., Frucor Beverages Group Limited, Frucor Suntory New Zealand Limited, Fujifilm Corporation, Futura Medical Corp., Galderma Laboratories, L.P., Game Plan Holdings, Inc., GE Healthcare Limited, Gelesis Holdings, Inc. (OTCPK:GLSH), Genentech, Inc., GeneraMedix, Inc., Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B), Germed Farmacêutica Ltda., Glanbia plc (ISE:GL9), Glenmark Pharmaceuticals, Inc., GNC Holdings, Inc., Grifols, S.A. (BME:GRF), Grupe Maspex sp. z o.o, Grupo Petrópolis Ltda., Guided Therapeutics, Inc. (OTCPK:GTHP), Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR), GW Pharmaceuticals Limited, H2 Pharma, Ha Tay Pharmaceutical JSC (HNX:DHT), Haffkine Bio-Pharmaceutical Corporation Ltd., HELL ENERGY Magyarország Kft., Henkel AG & Co. KGaA (XTRA:HEN3), Hikal Limited (BSE:524735), Hikma Pharmaceuticals USA Inc., Hoffmann-La Roche Inc., Hologic, Inc. (NasdaqGS:HOLX), Honest Tea, Inc., ICOS Corporation, Illumina, Inc. (NasdaqGS:ILMN), Imexpharm Corporation (HOSE:IMP), Incyte Corporation (NasdaqGS:INCY), InflaRx N.V. (NasdaqGS:IFRX), Insight Pharmaceuticals Corporation, INSYS Therapeutics, Inc. (Out of Business), Intech Biopharm Corporation (TPEX:6461), Intersect ENT, Inc., Ipsen S.A. (ENXTPA:IPN), Iroko Pharmaceuticals, LLC, Jamjoom Pharmaceuticals Factory Company (SASE:4015), Janssen Pharmaceutical K.K., Janssen Therapeutics, Janssen-Cilag Farmaceutica SA, Japan Tobacco Inc. (TSE:2914), Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., Johnson & Johnson (NYSE:JNJ), Johnson & Johnson Consumer Inc., Johnson & Johnson LLC, Johnson & Johnson Private Limited, K+S Aktiengesellschaft (XTRA:SDF), Kao Corporation (TSE:4452), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), Kering SA (ENXTPA:KER), Kimberly-Clark Corporation (NYSE:KMB), Kingsley Beverages, Kitasato Daiichi Sankyo Vaccine Co., Ltd., Knjaz Milos A.D., Kofola CeskoSlovensko a.s. (SEP:KOFOL), Koninklijke Philips N.V. (ENXTAM:PHIA), Kos Pharmaceuticals, Inc., Kraft Foods Group, Inc. (Acquired), Kubota Pharmaceutical Holdings Co., Ltd. (TSE:4596), KYORIN Pharmaceutical Co., Ltd. (TSE:4569), Kyowa Kirin Co., Ltd. (TSE:4151), L'Oréal S.A. (ENXTPA:OR), Laboratorio Franco Colombiano Lafrancol S.A.S., Laboratory Corporation of America Holdings (NYSE:LH), Lamdong Pharmaceutical Joint Stock Company (HNX:LDP), LANXESS Corporation, Living Essentials Marketing, LLC, Lotte Chilsung Beverage Co., Ltd. (KOSE:A005300), LVMH Moët Hennessy - Louis Vuitton, Société Européenne (ENXTPA:MC), Macro Group Pharmaceuticals (Macro Capital) S.A.E (CASE:MCRO), Maspex Sp. z o.o., Matinas BioPharma Holdings, Inc. (NYSEAM:MTNB), Mayne Pharma Group Limited (ASX:MYX), MBG International Premium Brands GmbH, McKesson Corporation (NYSE:MCK), MEDA Pharma GmbH & Co. KG, Medicure Inc. (TSXV:MPH), Medifocus, Inc., Medtronic plc (NYSE:MDT), Mekophar Chemical Pharmaceutical Joint Stock Company, Merck & Co., Inc. (NYSE:MRK), Merck (Schweiz) AG, Merck KGaA (XTRA:MRK), Merck Serono S.A., Merck Sharp & Dohme LLC, Meridigen Biotech Co., Ltd., Millennium Pharmaceuticals, Inc., Missile Inc, Mitsubishi Tanabe Pharma Corporation, Moderna, Inc. (NasdaqGS:MRNA), Mondelez International, Inc. (NasdaqGS:MDLZ), Monster Beverage Corporation (NasdaqGS:MNST), MSD Oss B.V., MYOS RENS Technology Inc. (Acquired), N.V.E., Inc., Natura Beverages, Inc, Nerhadou International for Pharmaceuticals and Nutraceuticals, Neurobrands, LLC, New Products Group, Inc., Nocco Sverige, Novartis AG (SWX:NOVN), Novartis Consumer Health, Inc., Novartis International AG, Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals UK Limited, Novavax, Inc. (NasdaqGS:NVAX), Novo Nordisk A/S (CPSE:NOVO B), NOW Health Group, Inc., Oaklawn Park Cemetery and Funeral Home, Inc., Ocean Nutrition Canada Limited, Omeros Corporation (NasdaqGM:OMER), OMRIX biopharmaceuticals LTD, Ono Pharmaceutical Co., Ltd. (TSE:4528), OPC Pharmaceutical Joint Stock Company (HOSE:OPC), OptiNose, Inc. (NasdaqGS:OPTN), Orexigen Therapeutics, Inc. (Out of Business), Osotspa Public Company Limited (SET:OSP), Otsuka Pharmaceutical Co., Ltd., Oy Sinebrychoff Ab, Pacgen Life Science Corporation, Panacea Biotec Limited (NSEI:PANACEABIO), Perrigo Company plc (NYSE:PRGO), Pfizer Consumer Healthcare, Pfizer Inc. (NYSE:PFE), Pfizer Nutrition Inc., Pharco Pharmaceuticals Inc., Pharmedic Pharmaceutical Medicinal Joint Stock Company (HNX:PMC), PINELLI, spol. s r.o., Piramal Enterprises Limited (BSE:500302), PLx Pharma Winddown Corp., POWER HORSE Energy Drinks GmbH, Poxel S.A. (ENXTPA:POXEL), Precigen, Inc. (NasdaqGS:PGEN), Prestige Brands, Inc., Procaps Group S.A. (NasdaqGM:PROC), PROCEPT BioRobotics Corporation (NasdaqGM:PRCT), ProMIS Neurosciences, Inc. (NasdaqCM:PMN), Protein Sciences Corporation, Purdue Pharma L.P., Pymepharco Joint Stock Company (UNQ-VNM:PME), Qiagen N.V. (NYSE:QGEN), Quala S.A., Quest Diagnostics Incorporated (NYSE:DGX), Quotient Limited, Ranir, LLC, Reading International, Inc. (NasdaqCM:RDI), Reata Pharmaceuticals, Inc., Reckitt Benckiser Group plc (LSE:RKT), Reignwood Group, Rhodia S.A., Ritalin Company, Rite Foods Ltd, Roche Holding AG (SWX:ROG), Rockstar, Inc., Rugby Laboratories, Inc., RxUSA Wholesale Inc., RxUSA, Inc., Sandoz GmbH, Sanofi (ENXTPA:SAN), Sanofi India Limited (BSE:500674), Sanofi Pasteur SA, Sanofi SA, Sanofi-Aventis A.E.B.E., Sanofi-Aventis U.S. LLC, Seqirus UK Limited, Serum Institute of India Pvt. Ltd., Shionogi & Co., Ltd. (TSE:4507), Shiseido Company, Limited (TSE:4911), Smart for Life, Inc. (NasdaqCM:SMFL), Sopharma AD (BUL:SFA), South Beach Beverage Company, Inc., Speed Energy Drink, LLC, Spimaco Egypt Co., SPM Corporation (HOSE:SPM), STADA Arzneimittel Aktiengesellschaft, SteadyMed Ltd., Sumitomo Pharma America, Inc., Sunstar Americas, Inc., Tabuk Pharmaceutical Manufacturing Company, Tecnoquimicas S.A., TerSera Therapeutics LLC, Teva Pharmaceutical Industries Limited (NYSE:TEVA), Teva Pharmaceutical Industries Ltd., Portfolio Of Generic Pharmaceutical Products (Acquired), Teva Pharmaceuticals USA, Inc., The Coca-Cola Company (NYSE:KO), The Estée Lauder Companies Inc. (NYSE:EL), The Honey Pot Company, LLC, The Procter & Gamble Company (NYSE:PG), Theratechnologies Inc. (TSX:TH), TheWorks.co.uk plc (LSE:WRKS), Tivic Health Systems, Inc. (NasdaqCM:TIVC), Transpact Enterprises Limited (BSE:542765), Traphaco Joint Stock Company (HOSE:TRA), TTY Biopharm Company Limited (TPEX:4105), Unilever PLC (LSE:ULVR), United Pharma Vietnam, United Therapeutics Corporation (NasdaqGS:UTHR), Universal Nutrition PLLC, Upsher-Smith Laboratories, LLC, Urologix, Inc. (OTCPK:ULGX), Urovant Sciences Ltd., Valeritas Holdings, Inc. (Out of Business), Valneva SE (ENXTPA:VLA), VBI Vaccines Inc. (NasdaqCM:VBIV), Viatris Inc. (NasdaqGS:VTRS), Vien Dong Pharmaceutical Joint Stock Company, Vitabiotics Ltd., Vital Pharmaceuticals, Inc., VIVUS, Inc., Wacker Chemie AG (XTRA:WCH), Wisynco Group Limited (JMSE:WISYNCO), Wockhardt Limited (NSEI:WOCKPHARMA), X4 Pharmaceuticals, Inc. (NasdaqCM:XFOR), Xl Energy Marketing Sp Z O O, Zydus Lifesciences Limited (NSEI:ZYDUSLIFE)

M&A Advisors
Allen & Overy LLP, Allen & Overy LLP (Brussels), Amstutz Greuter, Arkle Associates Limited, Asters, AZB & Partners, Baker & McKenzie LLP, Baker & Mckenzie LLP, London, Blake, Cassels & Graydon LLP, Bonelli Erede Pappalardo Studio Legale, Bredin Prat & Associes, Citigroup Global Markets Limited, Citigroup Inc. (NYSE:C), Cleary Gottlieb Steen & Hamilton LLP, Cleary Gottlieb Steen & Hamilton LLP, Crosstree Capital Partners Inc., Davis Polk & Wardwell LLP, Dechert LLP, Dechert LLP, Ernst & Young UK, Investment Banking Arm, Goldman Sachs & Co. LLC, Greenhill & Co. International LLP, Greenhill & Co., Inc. (NYSE:GHL), Hengeler Mueller Partnerschaft von Rechtsanwälten mbB, J.P. Morgan Cazenove Limited, JPMorgan Chase & Co. (NYSE:JPM), Khaitan & Co., King & Spalding LLP, Latham & Watkins (London) LLP, Latham & Watkins LLP, Lazard & Co., Limited, Lazard Freres & Co. LLC, Lazard Ltd (NYSE:LAZ), Lehman Brothers Inc., Linklaters LLP, Mannheimer Swartling Advokatbyrå Aktiebolag, Morgan Stanley & Co. LLC, Morrison & Foerster LLP, Nagashima Ohno & Tsunematsu, Niederer, Kraft & Frey, Nomura International Plc, Paul, Weiss, Rifkind, Wharton & Garrison LLP, PJT Partners (UK) Limited, PJT Partners Inc. (NYSE:PJT), PJT Partners LP, PricewaterhouseCoopers LLP, PricewaterhouseCoopers LLP, Reed Smith LLP, Russell McVeagh, Shearman & Sterling LLP, Sidley Austin LLP, Slaughter and May, Soewito Suhardiman Eddymurthy Kardono, Stikeman Elliott LLP, Studio Pirola Pennuto Zei & Associati, Studio Professionale Associato a Baker & McKenzie, The Goldman Sachs Group, Inc. (NYSE:GS), UBS Investment Bank, Udo Udoma & Belo-Osagie, Wachtell, Lipton, Rosen & Katz LLP, Zaoui & Co Ltd.


Advisors
Most Recent Auditor
Deloitte & Touche LLP
M&A Advisors
Allen & Overy LLP, Allen & Overy LLP (Brussels), Amstutz Greuter, Arkle Associates Limited, Asters, AZB & Partners, Baker & McKenzie LLP, Baker & Mckenzie LLP, London, Blake, Cassels & Graydon LLP, Bonelli Erede Pappalardo Studio Legale, Bredin Prat & Associes, Citigroup Global Markets Limited, Citigroup Inc. (NYSE:C), Cleary Gottlieb Steen & Hamilton LLP, Cleary Gottlieb Steen & Hamilton LLP, Crosstree Capital Partners Inc., Davis Polk & Wardwell LLP, Dechert LLP, Dechert LLP, Ernst & Young UK, Investment Banking Arm, Goldman Sachs & Co. LLC, Greenhill & Co. International LLP, Greenhill & Co., Inc. (NYSE:GHL), Hengeler Mueller Partnerschaft von Rechtsanwälten mbB, J.P. Morgan Cazenove Limited, JPMorgan Chase & Co. (NYSE:JPM), Khaitan & Co., King & Spalding LLP, Latham & Watkins (London) LLP, Latham & Watkins LLP, Lazard & Co., Limited, Lazard Freres & Co. LLC, Lazard Ltd (NYSE:LAZ), Lehman Brothers Inc., Linklaters LLP, Mannheimer Swartling Advokatbyrå Aktiebolag, Morgan Stanley & Co. LLC, Morrison & Foerster LLP, Nagashima Ohno & Tsunematsu, Niederer, Kraft & Frey, Nomura International Plc, Paul, Weiss, Rifkind, Wharton & Garrison LLP, PJT Partners (UK) Limited, PJT Partners Inc. (NYSE:PJT), PJT Partners LP, PricewaterhouseCoopers LLP, PricewaterhouseCoopers LLP, Reed Smith LLP, Russell McVeagh, Shearman & Sterling LLP, Sidley Austin LLP, Slaughter and May, Soewito Suhardiman Eddymurthy Kardono, Stikeman Elliott LLP, Studio Pirola Pennuto Zei & Associati, Studio Professionale Associato a Baker & McKenzie, The Goldman Sachs Group, Inc. (NYSE:GS), UBS Investment Bank, Udo Udoma & Belo-Osagie, Wachtell, Lipton, Rosen & Katz LLP, Zaoui & Co Ltd.
Public Offering Advisors
Cleary Gottlieb Steen & Hamilton LLP


Most Recent Auditor
Deloitte & Touche LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
CFRA Equity Research
Nurhayati, Wan
Oct 07, 2023 04:23 PM
GSK
GSK plc
Reports
9
CFRA Equity Research
Nurhayati, Wan
Oct 07, 2023 11:01 AM
GSK
GSK plc
Reports
9
New Constructs, LLC

Oct 06, 2023 08:16 PM
GSK
GSK: Forensic Stock Earnings & Valuation
Reports
6
GlobalData

Oct 06, 2023 06:08 AM
GSK
GSK plc (GSK.LON) - Medical Equipment - Deals and Alliances Profile
Reports
177
Barclays
Field, Emily
Oct 06, 2023 05:08 AM
GSK
GSK plc: Weekly RSV launch tracker: Arexvy strong launch continues
Reports
10
GlobalData

Oct 06, 2023 12:24 AM
GSK
GSK plc (GSK.LON) - Financial and Strategic SWOT Analysis Review
Reports
952
S&P Global Compustat

Oct 05, 2023 03:17 AM
GSK
GSK plc 2023_10_05
Reports
18
Marktfeld
Paraskevopoulos, Michail
Oct 05, 2023 01:01 AM
GSK
GSK plc: Ownership Timelines & Shareholder Analytics (October 2023)
Reports
21
Wright Investors' Service Inc.

Oct 03, 2023 01:34 PM
GSK
Wright Industry Averages:  Pharmaceuticals & Biotechnology (United Kingdom)
Reports
50
Deutsche Bank
Papadakis, Emmanuel Douglas
Oct 02, 2023 02:06 PM
GSK
GSK: Weekly retail rx tracker
Notes
18


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Dodge & Cox

380,981,012

9.40

9,663.4

Jul-03-2023


BlackRock, Inc.

329,506,506

8.13

8,357.7

Jul-03-2023


The Vanguard Group, Inc.

182,374,737

4.50

4,625.8

Jul-03-2023


Norges Bank Investment Management

95,303,621

2.35

2,417.3

Jul-03-2023


State Street Global Advisors, Inc.

88,757,071

2.19

2,251.3

Jul-03-2023


Legal & General Investment Management Limited

83,609,272

2.06

2,120.7

Jul-03-2023


Schroder Investment Management Limited

66,617,924

1.64

1,689.7

Jul-03-2023


GlaxoSmithKline Employee Trust

63,852,032

1.58

1,619.6

Jul-03-2023


UBS Asset Management AG

62,275,465

1.54

1,579.6

Jul-03-2023


Silchester International Investors LLP

54,806,315

1.35

1,390.1

Jul-03-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Societe Generale Group, Banking Investments
29,753,619
16,947,144
Coöperatieve Centrale Raiffeisen-Boerenleenbank B.A., Asset Management Arm
12,687,509
9,837,509
Canadian Imperial Bank of Commerce, Asset Management Arm
13,218,494
9,006,486
Goldman Sachs Group, Investment Banking and Securities Investments
12,241,164
8,334,918
Mondrian Investment Partners Limited
45,954,726
8,268,317

Top Sellers
Sellers
Common Stock Equivalent Held
Change
BNP Paribas, Private & Investment Banking Investments
14,983,888
(12,399,863)
Neuflize OBC Asset Management
0
(12,238,297)
National Bank Investments Inc.
6,243,834
(10,454,829)
Royal Bank of Canada, Banking & Securities Investments
12,893,764
(9,692,521)
RBS Asset Management Ltd.
0
(9,484,477)


Projects Summary
Project Name
Company Role
Project Status
Date Created
Last Updated
Deal Size($mm)
Project Raven
Target
Research
Jun-24-2020
Jul-06-2020
-


S&P Global Ratings Credit Ratings
Debt Type (Rating Type)
Current Rating
Rating Date
Current CreditWatch / Outlook
Current CreditWatch / Outlook Date
Issuer Credit Rating (Local Currency LT)
A
Apr-07-2020
Stable
4/7/2020 12:15:44 PM
Issuer Credit Rating (Local Currency ST)
A-1
Feb-18-2008
-
-
Issuer Credit Rating (Foreign Currency LT)
A
Apr-07-2020
Stable
4/7/2020 12:15:44 PM
Issuer Credit Rating (Foreign Currency ST)
A-1
Feb-18-2008
-
-


News Headlines
Date/Time
Headline
Source
Sep-13
Coherus BioSciences Acquires Surface Oncology
Marketline - Deals
Sep-13
CureVac publishes financial results for the second quarter and first half of 2023 and provides information on its business development
India Pharma News
Sep-13
Confo Therapeutics Appoints Stephen Dowd as Chief Business Officer
ENP Newswire
Sep-12
Coherus BioSciences Acquires Surface Oncology
Marketline - Deals


Company Coverage
This company is not on any Coverage List.

Products
1070806 (Future), 1120212 + BKM120 (Future), 1265744 (Future), 1292263 (Future), 1322322 (Future), 1322888 (Future), 1325756 (Future), 1399686 (Future), 1440115 (Future), 1521498 (Future), 1614235 (Future), 1795091 (Future), 1995057 (Future), 2018682 (Future), 2110183 (Future), 2126458 (Future), 2141795 (Future), 2190915 (Future), 2245035 (Future), 2245840 (Future), 2248761 (Future), 2256098 (Future), 2256294 (Future), 2269557 (Future), 2285921 (Future), 2330672 (Future), 2330811 (Future), 2336805 (Future), 2339345 (Future), 2374697 (Future), 239512 (Future), 2398852 + 2315698 (Future), 2401502 (Future), 2485852 (Future), 249320 (Future), 2556286 (Future), 256066 (Future), 256073 (Future), 2586184 (Future), 2586881 (Future), 2618960 (Future), 2636771 (Future), 2646264 (Future), 2647544 (Future), 2661380 (Future), 2696266 (Future), 2696274 (Future), 2696275 (Future), 26962774 (Future), 2798745 (Future), 2816126 (Future), 2831781 (Future), 2838232 (Future), 2849466 (Future), 2857916 (Future), 2862277 (Future), 2878175+RG101 (Future), 2879552 (Future), 2881078 (Future), 2890457 (Future), 2894512 (Future), 2904545 (Future), 2941266 (Future), 2981278 (Future), 2982772 (Future), 29987281 (Future), 3008356 (Future), 3036656 (Future), 3050002 (Future), 3052230 (Future), 3117391 (Future), 315234 (Future), 3174998 (Future), 3179106 (Future), 3186899 (Future), 3196165 (Future), 3228836 (Future), 3326595 (Future), 3342830 (Future), 3368715 (Future), 33777942 (Future), 33894041 (Future), 3437949 (Future), 3439171 (Future), 3494245 (Future), 3511294 (Future), 3528869 (Future), 3536819 (Future), 3536852 (Future), 3536867 (Future), 3537142 (Future), 356278 (Future), 3640254 (Future), 3684934 (Future), 3732394 (Future), 3739937 (Future), 3745417 (Future), 3772701 (Future), 3772847 (Future), 3810109 (Future), 3844766 (Future), 3845097 (Future), 3858279 (Future), 3882347 (Future), 3884464 (Future), 3888130 (Future), 3901961 (Future), 3915393 (Future), 3923868 (Future), 3943104 (Future), 3965193 (Future), 3993129 (Future), 4004280 (Future), 4011499 (Future), 4023393 (Future), 4074386 (Future), 4077164 (Future), 4106647 (Future), 4172239 (Future), 4178116 (Future), 4182137 (Future), 4348413 (Future), 4362676 (Future), 4381562 (Future), 4382276 (Future), 4388067 (Future), 4396687 (Future), 4406371 (Future), 4428859 (Future), 4429016 (Future), 4524184 (Future), 4527226 (Future), 4532990 (Future), 5101955 (Future), 5101956 (Future), 5251738 (Future), 525762 (Future), 573719 + Vilanterol (Future), 5HT4 Agonist, 6097608 (Future), 610677 (Future), 649868 (Future), 656933 (Future), 705498 (Future), 742457 (Future), 768974 (Future), 870086 (Future), 933776 (Future), 961081 (Future), 961081 + Fluticasone Furoate (Future), Abreva, Abreva Conceal, Abtei, Activir, ACWY Vax, ADA-SCID Gene Therapy, Adartrel, Adoair, Advair Diskus, Advil, Advil Dual Action, Agenerase, Albendazole Tablets, Alitretinoin (Future), Alkeran, Alli, Alluna, Altabax, Altargo, Ambirix, Ambrisentan, Amerge, Amoxil, AMP-224 (Future), Anacor (Future), Andropatch, Anectine, Anoro, Anoro Ellipta, APN01 (Future), Apretude, Aquafresh, AREPANRIX, AREXVY Vaccine (Future), Argatroban, Arixtra, Arnuity Ellipta, Arranon, Arzerra, Astringosol, Atriance, Augmentin, Augmentin ES-600, Augmentin XR, Avamys/Veramyst, Avandamet, Avandaryl, Avandia, Avodart, Avolve, Axid, Bactroban, BC Powder, Beano, Becloforte, Becodisks, Beconase, Beconase Allergy and Hayfever, Beconase Aq. Nasal Spray, Becotide, Becotide/Beclovent, Beechams, Belantamab Mafodotin, Benlysta, Benlysta + Rituxan (Future), Benlysta SC, Bepirovirsen (Future), Betnovate, Bexsero, Binaca, Bintrafusp Alfa, Biotene, Blenrep, Bonviva/Boniva, Boost, Boostrix, Botox, Breathe Right, Breo, BVL-GSK098 (Future), Cabenuva, Cabotegravir (Future), Cabotegravir LA + Rilpivirine (Future), Caltrate, Camicinal (Future), Ceftin, Celsentri, Centrum, Cervarix, Cervatrix (Future), Cetebe, Chap-et, ChapStick, Chill Dood, Chlorhexamed, Chlorproguanil (Future), Cholinex, Cicatrin, Closed Triple Therapy (Future), Cobolimab (Future), Coldrex, Combivir, Combodart, Commit Lozenge, Committed Quitters, Coreg, Coreg CR, Coreg CR+ACE Inhibitor (Future), Coreg IR, Corega, Corsodyl, Cortal, Corticosteroid, Covifenz, Crocin, Crocin Cold n Flu, CTP-298, CTP-518 (Future), Cutivate, CV2CoV (Future), Danirixin (Future), Danirixin i.v (Future), Darapladib (Future), Daraprim, Daronrix (Future), Darotropium (Future), Day/Night Nurse, Debrox, Dectova IV, Denagliptin (Future), Depemokimab (Future), Dequadin, Dermovate, Dexedrine, Diagnostic Influenza Tests (Future), Digibind, Dilmapimod (Future), Distribution of Baycol, Distribution of Citrucel, Distribution of MED2002 (Future), Dolex, Dolutegravir, Dolutegravir + Abacavir (Future), Dolutegravir + Abacavir Sulphate + Lamivudine (Future), Dolutegravir + Lamivudine, Doralese Tiltabs, Dovato, Dr. Best, DREAMM-9 (Future), Drisapersen (Future), DTaP-IPV Vaccine (Future), Duac, Duodart/Jalyn, Dutasteride+Testosterone (Future), Duvroq/Jesduvroq, DV1179 (Future), Dyazide, DynaCirc CR, Ebola (Future), Ecotrin, Efcortelan, Elesclomol (Future), ELLIPTA, Eltroxin (Future), Emergen-C, Emo-Cort, Encepur, Engerix, ENO, Entrareg/Entereg, Epivir-HBV, Epstein-Barr Virus Vaccine (Future), Epzicom/Kivexa, Etaquine (Future), Eumovate, Eunova, Evoclin, Excedrin, Extina, Fabior, Farglitazar (Future), Fenbid, Fendrix, Fenistil, Feosol, Fesovit, FiberChoice, Firategrast (Future), Flixonase Allergy, Flixonase/Flonase Piriton, Flixotide/Flovent, Flolan, Flu Pre-pandemic (Future), Flu Vaccine, Fluarix Tetra, Fluarix/ FluLaval, Fluticasone Furoate + Umeclidinium (Future), Fluticasone Furoate + Vilanterol + Umeclidinium (Future), Fluticasone Furoate Monotherapy (Future), Foretinib (Future), Formigran, Fortaz, Fortum, FP-1039/GSK3052230 (Future), Fraxiparine, Gaviscon, Gepotidacin (Future), Geritol, Globorix (Future), Gly-Oxide, Goodys Powder, GPB510 (Future), Granufink, Group B Streptococcus (Future), GSK 3943104A (Future), GSK1838262/xp13512 (Future), GSK2251052, GSK3359609 (Future), GSK3377794 (Future), GSK4428859A (Future), GSK6097608 (Future), GSK786 (Future), GT622 (Future), GW642444 (Future), Havrix, Hepatitis, Hepatitis C (Future), Hepatyrix, Hepsera, Heptavalent Combination Vaccines (Future), Hiberix, Hibitane, Hinds, Horizant, Horlicks Growth+, HuMax-CD20 (Future), Hycamtin, Hydrozole, HZ/su (Future), Iboctadekin+Doxil (Future), Imigran Recovery, Imigran/Imitrex, Imitrex, Impruv, Imuran, Incruse Ellipta, Infanrix, Infanrix IPV, Infanrix IPV + HIB, Innopran XL, Insto, Integrilin, Iodex, Iodosan, IONIS-GSK4-L (Future), ISIS-TTRRx (Future), Itraconazole Tablets, Jemperli, JTP-74057 (Future), Juluca, Junior Horlicks Biscuits, Kemadrin Tablets, Kinrix, Kozenis, Lactacyd, Lamictal, Lamictal IR, Lamictal ODT, Lamictal XR, Lamisil, Lanoxin, Lanvis, Lapdap, Latozinemab (Future), Lersivirine, Letetresgene Autoleucel (Future), Leukeran, Levitra, Lexiva/Telzir, Libenar, Linerixibat (Future), Liskonum, Lmitrex, Losmapimod (Future), Lovaza, Lunivia (Future), Macleans, MAGE-A3 (Future), Malarone, Maltova, Mapatumumab (Future), Massengill, Maxinutrition, Medacalm, Mejoral, Mekinist, MenHibrix, Menitorix, Menjugate, Menveo, Mepron, Migalastat HCl (Future), Migalastat HCl + ERT (Future), Mivacron, Molibresib (Future), Momelotinib (Future), Mosquirix, Mother’s Horlicks, Myleran, Name alli, Naramig, Nemiralisib (Future), Nexium, Nicabate, Nicabate CQ, Nicoderm, Nicorette, Nicorette Mini Lozenges, Nicotinell, Nimbex, Nimenrix, NiQuitin CQ, NTHi (Future), NTHi-Pneumo (Future), Nucala, Nutribar, NY-ESO-1 (Future), Nytol, Oasis, oderm CQ, Odol, Odol Med 3, Oilatum, OncoMed (Future), Orvepitant (Future), Os-cal, Otelixizumab (Future), Otilimab, Otosporin Ear Drops, Otrivin, Oxytocin (Future), Ozanezumab (Future), P501 (Future), Panadeine, Panadol, Panadol Cold and Flu, Panadol Extra Advance, Pandemrix, PanOxyl, Brevoxyl and Clindoxyl, Parnate, Parodontax/Corsodyl, Patrome (Future), Paxil CR, Paxil IR, Pazopanib, Pediarix, Pentostam, PF-232798 (Future), Phazyme, Physiogel, Piri Allergy, Piriteze, Piriton, Polident, Polident 5 Minute, Poligrip, Poligrip Ultra, Poliomyelitis, Potiga, PRAME (Future), Prepandrix, Preparation H, Priorix, Priorix Tetra, Prolia, Promacta, Pronamel, Propaderm, Pumarix (Future), Puri-Nethol, Pylorid, Quinvaxem, Rabipur, Radafaxine (Future), Raxibacumab, Relafen, Relenza, Relenza I.v (Future), Relovair (Future), Relvar Ellipta, Relvar/Breo Ellipta, Remoglifozin Etabonate (Future), Requip, ReQuip CR, REQUIP LP, Requip Modutab, Requip XL, Respiratory Syncytial Virus Vaccine (Future), Respontin Nebules, Retosiban (Future), Retrovir, Revolade, Rilapladib (Future), Robitussin, Ronacaleret (Future), Rosiglitazone XR (Future), Rotarix, Rukobia, Rutinoscorbin, Rythmol, Rythmol SR, S. Pneumoniae Paediatric Next Generation (Future), Sanfetrinem Cilexetil (Future), Santaris (Future), Scotts Emulsion, Selzentry, Sensodyne, Sensodyne Deep Clean, Sensodyne Rapid Relief, Sensodyne Sensitivity & Gum, Sensodyne True White, Sepracor (Future), Sepradex (Future), Septrin, SERETIDE DISKUS (Future), Seretide/Advair, Serevent, Seroxat/Paxil, Shigella (Future), Shingrix, Shringrix, Shumitect, Sirukumab (Future), Sitamaquine (Future), SKYCovione, Smokers' Health, Solabegron (Future), Solpadeine, Solzira (Future), Sominex, Soriatane, Sorilux, Stanback, Staphylococcus Aureus Vaccine (Future), Staxyn, Stiefel, Stiolto Respimat, Strimvelis, Sulphate + Lamivudine (Future), Super Poligrip, Super Wernets, Syncria (Future), Synflorix, Synthol, Tabloid, Tadalafil (Future), Tafenoquine, Tafinlar, Tagamet, Tanzeum/Eperzan, Tarextumab (Future), Targacept (Future), Targon, Tazarotene Foam (Future), Tebipenem HBr (Future), Tebipenem Pivoxil (Future), Theraflu, Therapeutic COPD (Future), Timentin, Tivicay, Toctino, ToleRx (Future), Toll-like Receptors (Future), Tracrium, Traficet-ENT (Future), Trametinib (Future), Trametinib + 2141795 (Future), Trametinib + Dabrafenib (Future), Trametinib Plus Palbociclib (Future), Trandate, Trelegy, Trelegy Ellipta, Treximet, Trimovate, Triumeq, Triumeq PD, Trizivir, Trobalt, TSR-022 (Future), TSR-033 (Future), Tums, TUMS Chewy Bites, TUMS Naturals, Twinrix, Tykerb + Armala (Future), TYKERB Plus (Future), Tykerb/Tyverb, Typherix, UK-453061 (Future), Ultiva, UMEC/VI (Future), Umeclidinium Bromide, Vaccine Track, Valda, Valtrex, Varicella Zoster Virus Vaccine (Future), Varilrix, Veltin, Ventodisks, Ventolin, Veramyst, Vercirnon (Future), Vesicare, Vestipitant (Future), Vestipitant +Paroxetine (Future), VH148 (Future), VidPrevtyn, Vilanterol, VIR-2482 (Future), Viva, Volatrol, Volibris, Volmax, Voltaren, Votrient, VRX698 (Future), VX-409 (Future), Wellbutrin, Wellbutrin IR, Wellbutrin SR, Wellbutrin XL, Wellvone, Women’s Horlicks, WT1 (Future), Xenical, Xevudy, Xgeva, XMT-2056 (Future), XP13512, Xyzal, Zantac, Zeffix, Zegerid Capsules, Zegerid Powder, Zejula, Zentel, Ziagen, Zinacef, Zinnat, Zofran, Zovirax, Zyban, Zyloric, Zyrtec


Upcoming Events
Date/Time
Type
Oct-12-2023
Conferences
Oct-12-2023 1:30 PM (UTC)
Company Conference Presentations
Oct-15-2023
Conferences
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Reporting Owner(s)
Source
Form Type
Size
4:40 AM
Oct-11-2023
GSK plc (LSE:GSK)

SEC
6-K
32 KB
12:00 AM
-
GSK plc (LSE:GSK)

RNS
Statement
17 KB
Oct-10-2023
Oct-10-2023
GSK plc (LSE:GSK)

SEC
6-K
57 KB
Oct-09-2023
-
GSK plc (LSE:GSK)

RNS
Re Agreement
34 KB
Oct-06-2023
Oct-06-2023
GSK plc (LSE:GSK)

SEC
6-K
63 KB
Oct-06-2023
Oct-06-2023
GSK plc (LSE:GSK)

SEC
6-K
46 KB
Oct-06-2023
-
GSK plc (LSE:GSK)

RNS
Disposal
28 KB
Oct-05-2023
-
GSK plc (LSE:GSK)

RNS
Disposal
30 KB
Oct-02-2023
-
GSK plc (LSE:GSK)
NEW YORK STOCK EXCHANGE LLC
SEC
25-NSE
4 KB
Oct-02-2023
Oct-02-2023
GSK plc (LSE:GSK)

SEC
6-K
17 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Symonds BA, CBE, FCA, Jonathan Richard (Non-Executive Chairman)
Sep-20-2023
Common Stock
1,900
48,877
Open Market Acquisition
1.98
Exchange Announcement
Rohner, Urs  (Independent Non-Executive Director)
Sep-20-2023
Common Stock
453
11,675
Open Market Acquisition
1.28
Exchange Announcement
Sikka, Vishal  (Independent Non-Executive Director)
Sep-20-2023
SPON ADS EACH REP 2 ORD SHS WI
790
40,859
Open Market Acquisition
88.37
Exchange Announcement
Barron F.A.C.C., M.D., Hal V. (Non-Executive Director)
Sep-20-2023
SPON ADS EACH REP 2 ORD SHS WI
219
11,327
Open Market Acquisition
0.30
Exchange Announcement
Dietz M.D., Ph.D., Harry C. (Independent Non-Executive Director)
Sep-20-2023
SPON ADS EACH REP 2 ORD SHS WI
220
11,378
Open Market Acquisition
90.91
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Symonds, Jonathan Richard
Non-Executive Chairman
44 20 8047 5000
-

Walmsley, Emma Natasha
CEO & Director
44 20 8047 5000
-

Brown, Julie Belita
CFO & Executive Director
44 20 8047 5000
-

Bancroft, Charles A.
Senior Independent Non-Executive Director
44 20 8047 5000
-

Rohner, Urs 
Independent Non-Executive Director
44 20 8047 5000
-

Anderson, Elizabeth McKee
Independent Non-Executive Director
44 20 8047 5000
-

Barron, Hal V.
Non-Executive Director
44 20 8047 5000
-

Beal, Anne C.
Independent Non-Executive Director
44 20 8047 5000
-

Becker, Wendy 
Non-Executive Director
44 20 8047 5000
-

Dietz, Harry C.
Independent Non-Executive Director
44 20 8047 5000
-

Goodman, Jesse L.
Independent Non-Executive Director
44 20 8047 5000
-

Sikka, Vishal 
Independent Non-Executive Director
44 20 8047 5000
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Walmsley, Emma Natasha
CEO & Director
44 20 8047 5000
-

Brown, Julie Belita
CFO & Executive Director
44 20 8047 5000
-

Ramakrishnan, Shobie 
Chief Digital & Technology Officer
44 20 8047 5000
-

Wood, Tony 
Chief Scientific Officer
44 20 8047 5000
-

Elton-Farr, Sarah 
Head of Investor Relations
+44 (0) 20 8047 5194
-

Ford, James 
Senior VP & Group General Counsel of Legal & Compliance
44 20 8047 5000
-

Jackson, Sally 
Senior Vice President of Global Communications & CEO Office
44 20 8047 5000
-

Redfern, David Simon
President of Corporate Development
44 20 8047 5000
-

Conrad, Diana 
Chief People Officer
44 20 8047 5000
-

Altshul, Amy 
Senior Vice President of Legal, R&D and Global Commercial Franchises
44 20 8047 5000
-

Branson, Kim 
Senior VP and Global Head of Artificial Intelligence & Machine Learning
44 20 8047 5000
-

Breuer, Thomas 
Chief Medical Officer of GSK Vaccines
44 20 8047 5000
-
-
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
